M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied for the treatment of breast cancer in women in the 1940s, but was never marketed.
The chemical synthesis of M2613 has been described:
The Grignard reaction between 1-(4-Ethoxyphenyl)-2-phenylethanone [38495-73-7] (1) and 4-Bromoanisole [104-92-7] (2) gives 3. Condensation with molecular bromine in the presence of glacial acetic acid completes the synthesis of M2613 (4). Alternately, Grignard reaction between 4-Ethoxy-4'-methoxybenzophenone [52886-92-7] (4) and benzyl bromide [100-39-0] (5) also yields 3.